Physician profile
Samer Alkhuja
NPI 1346299922
$6,802.98
in general payments reported to CMS, 2019-2025
16 companies · $62.43 in 2025
The $62.43 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $416 · 2021: $1,577 · 2022: $1,441 · 2023: $2,156 · 2024: $125 · 2025: $62.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,268 · Education: $74.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,267.94 |
| Education | $74.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,391.49 | 2020-2024 | Fasenra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,549.74 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Mallinckrodt Hospital Products INC. | $895.01 | 2020-2023 | Acthar |
| Esperion Therapeutics, INC. | $373.40 | 2021 | |
| Genentech USA, INC. | $344.81 | 2019-2023 | Xolair |
| Philips North America LLC | $253.65 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $236.35 | 2019 | |
| Amgen INC. | $184.64 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $163.37 | 2019-2021 | |
| Mannkind Corporation | $125.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $79.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $63.14 | 2019 | |
| Inogen, INC. | $56.93 | 2023 | Inogen One G3 Oxygen Concentrator, Inogen One G5 Oxygen Concentrator - Bluetooth |
| Actelion Pharmaceuticals US, INC. | $42.50 | 2019 | |
| Insmed, INC. | $29.06 | 2019-2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $14.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Alkhuja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.